Detail of "25024-53-7"

CAS Number:
25024-53-7
Name:
L-Histidine,N-[(1,1-dimethylethoxy)carbonyl]-1-(2,4-dinitrophenyl)-
Superlist Name:
N-(tert-Butoxycarbonyl)-1-(2,4-dinitrophenyl)-L-histidine
Molecular Structure:
Formula:
C₁₇H₁₉N₅O₈
Molecular Weight:
421.36
Deleted CAS:
95485-28-2
Synonyms:
Histidine,N-carboxy-1-(2,4-dinitrophenyl)-, N-tert-butyl ester, L- (8CI);Boc-His(Dnp)-OH;
EINECS:
246-569-0
Density:
1.49 g/cm³
Melting Point:
98-100 °C (dec.)
Boiling Point:
663.2 °C at 760 mmHg
Flash Point:
354.9 °C
Safety:
22-24/25 Details

Display：

Please post your buying leads,so that our qualified suppliers will soon contact you!
*Required Fields

Protease-catalyzed synthesis of melanocyte-stimulating hormone (MSH) fragments: Protease-catalyzed synthesis of melanocyte-stimulating hormone (MSH) fragments. Kullmann, Willi (Max-Planck-Inst. Biophys. Chem., Goettingen, Fed. Rep. Ger.). J. Protein Chem., 2(4), 289-301 (English) 1983. 90123-64-1 and 25024-53-7 are cas registry numbers of chemicals which are used as reagents here. CODEN: JPCHD2. ISSN: 0277-8033. DOCUMENT TYPE: Journal CA Section: 34 (Amino Acids, Peptides, and Proteins) Section cross-reference(s): 7 Trypsin, a-chymotrypsin, papain, carboxypeptidase Y, and thermolysin served as catalysts for the protease-controlled synthesis of some fragments of MSH. To obviate proteolytic cleavage of peptide bonds, several expedients leading to the target peptides were developed. The enzymic procedure enabled under mild conditions the prepn. of the desired peptides whose amino acid compn. may cause complications during conventional syntheses. .

Hypocalcemic peptides and drugs containing these active principles: Hypocalcemic peptides and drugs containing these active principles. Milhaud, Gerard (Fr.). PCT Int. 25024-53-7 and 103451-85-0 are also occured in this study. Appl. WO 8603496 A1 19 Jun 1986, 21 pp. DESIGNATED STATES: W: JP, US; RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE. (World Intellectual Property Organization) CODEN: PIXXD2. CLASS: ICM: C07K007-10. ICS: A61K037-02. APPLICATION: WO 85-FR356 10 Dec 1985. PRIORITY: FR 84-18838 10 Dec 1984; FR 84-19958 28 Dec 1984. DOCUMENT TYPE: Patent CA Section: 34 (Amino Acids, Peptides, and Proteins) Section cross-reference(s): 1 Polypeptides I and II (X1 = Ser, Gly, Ala; X2 = Val, Leu; X3 = Lys, Thr; X4 = Leu, Tyr; X5 = Ser, Thr; X6 = Glu, Asp; X7 = Leu, Phe; X8 = His, Asn; X9 = Leu, Phe; X10 = Gln, His; X11 = Tyr, Phe; X12 = Arg, Gln; X13 = Asp, Asn, Ala; X14 = Val, Thr, Ile; X15 = Ala, Ser, Val; X16 = Thr, Val, Ala) were prepd. by solid-phase methods on benzhydrylamine resins. Thus, I (X1 = X15 = Ala, X2 = X14 = Val, X3 = Lys, X4 = X7 = X9 = Leu, X5 = Ser, X6 = Glu, X8 = His, X10 = Gln, X11 = Tyr, X12 = Arg, X13 = Asp, X16 = Thr) was prepd. by solid-phase synthesis. I and II lowered Ca levels in rats i.v., and they are useful in the treatment of osteoporosis. .